Baseline Symptom Score and Flow Rate Can Predict Failure of Medical Treatment of Lower Urinary Tract Symptoms: Prospective 12-year Follow-up Study

被引:2
|
作者
Mishriki, Said Fadel [1 ]
Aboumarzouk, Omar
Graham, John T.
Lam, Thomas B.
Somani, Bhaskar K.
机构
[1] Aberdeen Royal Infirm, Dept Urol, Aberdeen AB25 2ZN, Scotland
关键词
BENIGN PROSTATIC HYPERPLASIA; QUALITY-OF-LIFE; CLINICAL PROGRESSION; FINASTERIDE; SURGERY; THERAPY; MEN; MANAGEMENT; PLACEBO;
D O I
10.1016/j.urology.2012.08.104
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess predictors of failure of medical treatment of lower urinary tract symptoms (LUTS) and evaluate long-term outcome. METHODS Between January 1993 and September 1994, 178 men referred with LUTS were prospectively recruited. Assessments included maximum urine flow (Qmax), postvoiding residuals (PVR), transrectal ultrasound (TRUS) prostate volumes, American Urological Association symptom score, and validated quality of life (QOL) and bother scores. Treatment failure was defined as need for transurethral resection of the prostate (TURP). Data were collected at baseline, with final follow-up at 12 years. Univariate and multivariate analyses used Kaplan-Meier and the Cox proportional hazards regression model, respectively, to assess covariates on risk of failure and independent variable prognostic values. RESULTS Median follow-up was 7.9 years (range, 0-12 years). The mean QOL baseline score of 7.1 improved to 3.6 at 6 years and to 3.3 at 12 years (P<.05 for all). Fifty patients (28%) underwent TURP, with 36 undergoing TURP within 3 years. By univariate analysis, Qmax, AUA and bother scores, and PVR were significantly associated with treatment failure. Independent predictors of failure by multivariate Cox regression were Qmax (>15 vs <15 mL/s; hazard ratio, 3.37; 95% confidence interval, 1.74-6.52; P<.0001) and bother score (<13 vs >13; hazard ratio, 2.37; 95% confidence interval, 1.29-4.35; P=.005). At 12 years, AUA, QOL, and bother scores statistically improved compared with baseline (13 vs 8, 10 vs 6, and 5 vs 2, respectively). Limitations included attrition bias from nonresponders. CONCLUSION The beneficial effect of medical treatment persisted for up to 12 years. Treatment is more likely to fail within the first 3 years in patients with low baseline Qmax and high bother scores. UROLOGY 81: 390-395, 2013. (C) 2013 Elsevier Inc.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 43 条
  • [1] Baseline Symptom Score and Flow Rate Can Predict Failure of Medical Treatment of Lower Urinary Tract Symptoms: Prospective 12-year Follow-up Study EDITORIAL COMMENT
    Homma, Yukio
    UROLOGY, 2013, 81 (02) : 394 - 395
  • [2] Predictors for lower urinary tract symptoms and the urinary specific quality of life in prostate cancer patients: One-year follow-up
    Chen, Saint Shiou-Sheng
    Cheng, Tse-Chou
    Chiu, Li-Pin
    Tasi, Li-Yun
    Huang, Sheng-Shiung
    Tsay, Shiow-Luan
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (06) : 482 - 487
  • [3] Prognostic factors of heart failure with preserved ejection fraction: A 12-year prospective cohort follow-up study
    Wu, Cho-Kai
    Lee, Jen-Kuang
    Chiang, Fu-Tien
    Lin, Lian-Yu
    Lin, Jou-Wei
    Hwang, Juey-Jen
    Tseng, Chuen-Den
    Tsai, Chia-Ti
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 171 (03) : 331 - 337
  • [4] A Relevant Midterm ( 12 Months) Placebo Effect on Lower Urinary Tract Symptoms and Maximum Flow Rate in Male Lower Urinary Tract Symptom and Benign Prostatic Hyperplasia-A Meta-analysis
    Eredics, Klaus
    Madersbacher, Stephan
    Schauer, Ingrid
    UROLOGY, 2017, 106 : 160 - 166
  • [5] Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study
    Hendriks, Celine
    Drent, Marjolein
    De Kleijn, Willemien
    Elfferich, Marjon
    Wijnen, Petal
    De Vries, Jolanda
    RESPIRATORY MEDICINE, 2018, 138 : S24 - S30
  • [6] Can We Decide the Optimal Initial Treatment for Male Lower Urinary Tract Symptoms Patients with Overactive Bladder by the Most Bothersome Symptom? A Randomized, Prospective, Open-Label Study
    Yun, Jong Hyun
    Kim, Jae Heon
    Kim, Jae Ho
    Lee, Sang Wook
    Yang, Hee Jo
    Doo, Seung Whan
    Yang, Won Jae
    UROLOGIA INTERNATIONALIS, 2014, 93 (03) : 338 - 343
  • [7] Phamacological treatment of persistant lower urinary tract symptoms after a transurethral resection of the prostate is predictive of a new surgical treatment: 10 years follow-up study
    Nunzio, Cosimo De
    Franco, Antonio
    Lombardo, Riccardo
    Baldassarri, Valeria
    Borghesi, Alessandro
    Li Marzi, Vittorio
    Trucchi, Alberto
    Agro, Enrico Finazzi
    Tubaro, Andrea
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (02) : 722 - 727
  • [8] Long-Term Trajectories of Depressive Symptoms Among Children Affected by Parental HIV: A 12-Year Follow-Up Study
    Wu, Qinglu
    Zhao, Junfeng
    Zhao, Guoxiang
    Li, Xiaoming
    Du, Hongfei
    Chi, Peilian
    AIDS AND BEHAVIOR, 2022, 26 (08) : 2713 - 2722
  • [9] Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study
    Roehrborn, Claus G.
    Barkin, Jack
    Tubaro, Andrea
    Emberton, Mark
    Wilson, Timothy H.
    Brotherton, Betsy J.
    Castro, Ramiro
    BJU INTERNATIONAL, 2014, 113 (04) : 623 - 635
  • [10] Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
    Yamanishi, Tomonori
    Kaga, Kanya
    Fuse, Miki
    Shibata, Chiharu
    Kamai, Takao
    Uchiyama, Tomoyuki
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (12) : 1143 - 1148